GlassScriptPhysician profile
Gregory A Kelly
NPI 1982606984
$2,709.71
in general payments reported to CMS, 2019-2025
27 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $70.59 · 2022: $76.16 · 2023: $698 · 2024: $615 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $507.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.80 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $262.32 | 2019-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $202.29 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $166.28 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $156.93 | 2019-2025 | Wainua |
| Pfizer INC. | $151.68 | 2024-2025 | |
| Edwards Lifesciences Corporation | $129.60 | 2023 | |
| Scpharmaceuticals INC. | $105.60 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $97.36 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.94 | 2019-2023 | Lifevest |
| Abbott Laboratories | $59.80 | 2023-2024 | Cardiomems |
| Regeneron Healthcare Solutions, INC. | $58.37 | 2019-2023 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $57.65 | 2023-2025 | Opsumit, Opsynvi, Uptravi |
| Cvrx, INC. | $42.79 | 2024 | Barostim Neo System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.39 | 2019-2023 | Repatha |
| Philips North America LLC | $39.44 | 2019-2025 | Mcot |
| Bridgebio Pharma, INC. | $36.27 | 2025 | Attruby |
| Boston Scientific Corporation | $24.72 | 2023 | Watchman Access System |
| Kiniksa Pharmaceuticals, LTD. | $23.30 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $21.77 | 2024 | Arcalyst |
| Medicomp INC | $19.21 | 2023 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $16.78 | 2025 | Onpattro |
| Novo Nordisk INC | $15.87 | 2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $14.22 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 | |
| Amarin Pharma, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.